# InMed Pharmaceuticals Inc.: overview INM · Nasdaq · CIK 1728328 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/inm.md) · [Financials](/companies/inm/financials.md) · [Filings](/companies/inm/filings.md) · [Insiders](/companies/inm/insiders.md) Latest reported revenue: [$820.2k](/filings/0001213900-26-014996.md) for Q2 FY2026, three months to 2025-12-31, from the 10-Q filed Feb 11, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-014996). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,265](/filings/0001213900-25-107152.md) | [1,112](/filings/0001213900-26-014996.md) | [1,262](/filings/0001213900-25-042126.md) | [1,305 d](/filings/0001213900-25-090210.md) | [1,120](/filings/0001213900-25-107152.md) | [820](/filings/0001213900-26-014996.md) | not reported | not reported | | Gross margin | % | [39.0%](/filings/0001213900-25-107152.md) | [41.5%](/filings/0001213900-26-014996.md) | [13.9%](/filings/0001213900-25-042126.md) | [44.2% d](/filings/0001213900-25-090210.md) | [36.0%](/filings/0001213900-25-107152.md) | [22.5%](/filings/0001213900-26-014996.md) | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(132.7%)](/filings/0001213900-26-052920.md) | [(231.6%)](/filings/0001213900-26-052920.md) | [(168.1%)](/filings/0001213900-26-052920.md) | [(137.1%) d](/filings/0001213900-26-098419.md) | [(154.2%)](/filings/0001213900-26-052920.md) | [(247.3%)](/filings/0001213900-26-052920.md) | not reported | not reported | | Diluted EPS | $ per share | [(2.71)](/filings/0001213900-25-107152.md) | [(3.64)](/filings/0001213900-26-014996.md) | [(1.94)](/filings/0001213900-26-052920.md) | not reported | [(0.44)](/filings/0001213900-25-107152.md) | [(0.51)](/filings/0001213900-26-014996.md) | [(0.73)](/filings/0001213900-26-052920.md) | not reported | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.4](/filings/0001213900-22-058355.md) | [4.1](/filings/0001213900-24-082843.md) | [4.6](/filings/0001213900-25-090210.md) | [4.9](/filings/0001213900-25-090210.md) | not reported | | Gross margin | % | [39.8%](/filings/0001213900-23-080842.md) | [33.9%](/filings/0001213900-24-082843.md) | [23.9%](/filings/0001213900-25-090210.md) | [34.5%](/filings/0001213900-25-090210.md) | not reported | | Operating margin | % | [(1361.9%)](/filings/0001213900-23-080842.md) | [(192.2%)](/filings/0001213900-23-080842.md) | not reported | not reported | not reported | | Net margin | % | [(1361.9%)](/filings/0001213900-23-080842.md) | [(192.2%)](/filings/0001213900-24-082843.md) | [(166.9%)](/filings/0001213900-25-090210.md) | [(165.1%)](/filings/0001213900-26-098419.md) | not reported | | Diluted EPS | $ per share | [(33.17)](/filings/0001213900-23-080842.md) | [(3.25)](/filings/0001213900-24-082843.md) | [(20.14)](/filings/0001213900-25-090210.md) | [(8.36)](/filings/0001213900-26-098419.md) | [(3.12)](/filings/0001213900-26-098419.md) | | Free cash flow | $m | [(15.6)](/filings/0001213900-23-080842.md) | [(7.4)](/filings/0001213900-24-082843.md) | [(7.0)](/filings/0001213900-25-090210.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/inm/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-23 | [ADAR1 Capital Management, LLC](/insiders/1940272.md) | 10% owner | Purchase (P) | 4 | $1.32 | $5.28 | [Form 4](/filings/0001940272-26-000028.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $1.2m | 800,000 | | New +800,000 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $1.2m | 798,377 | | New +798,377 | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $503.8k | 325,000 | | New +325,000 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $379.8k | 245,025 | | New +245,025 | | [Ursa Fund Management, LLC](/funds/1693838.md) | 2026-06-30 | $195.0k | 125,800 | | New +125,800 | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $155.0k | 100,000 | | New +100,000 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $115.1k | 74,244 | | New +74,244 | | [SABBY MANAGEMENT, LLC](/funds/1535610.md) | 2026-06-30 | $69.7k | 44,970 | | Reduced −175,290 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $66.8k | 43,078 | | New +43,078 | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $50.7k | 32,685 | | New +32,685 | ## Recent filings [All 509 filings](/companies/inm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-18 | 17:11 ET | [8-K](/filings/0001213900-26-101492.md) | 3.01 Delisting notice; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-101492 | | 2026-09-09 | 16:31 ET | [10-K](/filings/0001213900-26-098419.md) | Annual report, period 2026-06-30 | 0001213900-26-098419 | | 2026-07-22 | 16:28 ET | [8-K](/filings/0001213900-26-080414.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-080414 | | 2026-07-10 | 16:02 ET | [8-K](/filings/0001213900-26-077127.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-077127 | | 2026-06-10 | 21:32 ET | [SCHEDULE 13D](/filings/0001213900-26-067514.md) | Ownership report, active investor | 0001213900-26-067514 | | 2026-06-10 | 06:01 ET | [8-K](/filings/0001062993-26-003132.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001062993-26-003132 | | 2026-05-19 | 10:32 ET | [8-K](/filings/0001213900-26-058795.md) | 1.01 Entry into a material agreement; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-058795 | | 2026-05-19 | 06:03 ET | [8-K](/filings/0001062993-26-002787.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 8.01 Other events; 9.01 Financial statements and exhibits | 0001062993-26-002787 | | 2026-05-07 | 18:12 ET | [8-K](/filings/0001062993-26-002371.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001062993-26-002371 | | 2026-05-06 | 17:25 ET | [10-Q](/filings/0001213900-26-052920.md) | Quarterly report, period 2026-03-31 | 0001213900-26-052920 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001213900-26-098419.md), filed Sep 9, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1728328 - Tickers: INM - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A1 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 04:34 ET. No prices; not investment advice.